Cargando…

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review

BACKGROUND: Febrile neutropenia (FN) is a prevalent and potentially life-threatening complication in patients with lymphoma receiving myelosuppressive chemotherapy. Pegfilgrastim is more effective than filgrastim as prophylaxis for FN. However, its usage has been limited because of its higher cost....

Descripción completa

Detalles Bibliográficos
Autores principales:	Gebremariam, Girma Tekle, Fentie, Atalay Mulu, Beyene, Kebede, Sander, Beate, Gebretekle, Gebremedhin Beedemariam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805270/ https://www.ncbi.nlm.nih.gov/pubmed/36585648 http://dx.doi.org/10.1186/s12913-022-08933-z

Ejemplares similares

Health-related quality of life and treatment satisfaction of patients with cardiovascular disease in Ethiopia
por: Tito, Kebron, et al.
Publicado: (2022)

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia
por: Gebretekle, Gebremedhin Beedemariam, et al.
Publicado: (2022)

Health-related quality of life of patients with type 2 diabetes mellitus at a tertiary care hospital in Ethiopia
por: Gebremariam, Girma Tekle, et al.
Publicado: (2022)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin’s Lymphoma: A Cost-Effectiveness Study
por: Ravangard, Ramin, et al.
Publicado: (2017)

Factors affecting cervical cancer screening uptake, visual inspection with acetic acid positivity and its predictors among women attending cervical cancer screening service in Addis Ababa, Ethiopia
por: Fentie, Atalay Mulu, et al.
Publicado: (2020)

Health-related quality of life and associated factors among cervical cancer patients at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia
por: Araya, Liya Teklu, et al.
Publicado: (2020)

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma
por: Kubo, Kohmei, et al.
Publicado: (2016)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
por: Morrison, Vicki A., et al.
Publicado: (2007)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Reliability and validity of the Amharic version of European Organization for Research and Treatment of cervical Cancer module for the assessment of health related quality of life in women with cervical cancer in Addis Ababa, Ethiopia
por: Araya, Liya Teklu, et al.
Publicado: (2019)

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
por: Bond, T Christopher, et al.
Publicado: (2017)

COVID-19 vaccine hesitancy among Ethiopian healthcare workers
por: Mohammed, Rihanna, et al.
Publicado: (2021)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Insulin injection practice and health related quality of life among individuals with diabetes at Tikur Anbessa Specialized Hospital, Ethiopia: a cross-sectional study
por: Negash, Zenebe, et al.
Publicado: (2023)

Days of Prophylactic Filgrastim Use to Reduce Febrile Neutropenia in Patients
por: Scott, Shane J., et al.
Publicado: (2003)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
por: Lee, Jihyoun, et al.
Publicado: (2018)

Multicentre point-prevalence survey of antibiotic use and healthcare-associated infections in Ethiopian hospitals
por: Fentie, Atalay Mulu, et al.
Publicado: (2022)

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
por: Al-Rabayah, Abeer A., et al.
Publicado: (2022)

Health professionals’ perceptions on local production and bioequivalence study of generic medicines: A cross-sectional survey of physicians and pharmacy professionals in Addis Ababa, Ethiopia
por: Selam, Muluken Nigatu, et al.
Publicado: (2023)

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
por: Weycker, Derek, et al.
Publicado: (2015)

Febrile neutropenia management in pediatric cancer patients at Ethiopian Tertiary Care Teaching Hospital
por: Mohammed, Husnia Bedewi, et al.
Publicado: (2019)

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
por: Aapro, M., et al.
Publicado: (2016)

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
por: Scholz, Markus, et al.
Publicado: (2009)

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021)

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015)

Assessment of Quality of Care Using Information on Patient Satisfaction at Adult Oncology Center of Tikur Anbessa Specialized Hospital, Ethiopia: A Cross-Sectional Study
por: Abate, Dessale, et al.
Publicado: (2020)

COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim
por: Gwak, Hongki, et al.
Publicado: (2022)

Practice of over-the-counter dispensary of antibiotics for childhood illnesses in Addis Ababa, Ethiopia: a simulated patient encounter study
por: Koji, Eyosait Mekonnen, et al.
Publicado: (2019)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
por: Sevinç, Alper, et al.
Publicado: (2018)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli, Désirée, et al.
Publicado: (2016)

Half of Prescribed Antibiotics Are Not Needed: A Pharmacist-Led Antimicrobial Stewardship Intervention and Clinical Outcomes in a Referral Hospital in Ethiopia
por: Gebretekle, Gebremedhin Beedemariam, et al.
Publicado: (2020)

Safety and tolerability of Peg-grafeel(™), a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
por: Talwar, Vineet, et al.
Publicado: (2017)

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
por: Aapro, Matti, et al.
Publicado: (2017)

Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
por: Kim, Do Young, et al.
Publicado: (2022)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
por: Innocenti, Rolando, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bncum7bvu204e9d1psjp5118hd